Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

Publication Date: January 1, 2015
Last Updated: March 14, 2022

Recommendations

The AGA recommends antiviral prophylaxis over no prophylaxis for patients at high risk undergoing immunosuppressive drug therapy. (Moderate, Strong)
Comments: Treatment should be continued for at least 6 months after discontinuation of immunosuppressive therapy (at least 12 months for B cell– depleting agents).
612

Overview

Title

Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

Authoring Organization